Comparative Pharmacology
Head-to-head clinical analysis: PHENYTOIN SODIUM versus ZARONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYTOIN SODIUM versus ZARONTIN.
PHENYTOIN SODIUM vs ZARONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. Prolongs inactivation of voltage-gated sodium channels, reducing repetitive firing of action potentials.
Ethosuximide (Zarontin) suppresses paroxysmal 3 Hz spike-and-wave activity associated with absence seizures. The mechanism may involve inhibition of T-type calcium channels in thalamic neurons, reducing oscillatory burst firing.
Loading dose: 15-20 mg/kg IV (not to exceed 50 mg/min) or oral (1000-1500 mg total in divided doses). Maintenance: 300-400 mg/day PO in 1-2 divided doses or IV (100 mg every 6-8 hours).
500 mg orally twice daily initially; may increase by 250 mg every 4-7 days. Maintenance: 1000-1500 mg/day in 2 divided doses; maximum 1500 mg/day.
None Documented
None Documented
Mean terminal half-life 22 ± 9 hours (range 7–42 hours), dose-dependent and saturable due to Michaelis-Menten kinetics; half-life increases with higher serum concentrations. Steady state achieved after 7–10 days.
60 hours (range 40-70) in adults; 30-40 hours in children (due to higher clearance); clinical context: steady-state reached in ~10-14 days; may be reduced with enzyme-inducing co-medications.
Primarily hepatic metabolism (CYP2C9, CYP2C19); <5% excreted unchanged in urine. Metabolites (majority p-HPPA) are excreted renally as glucuronide conjugates. Fecal elimination negligible (<2%).
Renal: ~40% as unchanged drug; hepatic metabolism accounts for ~60% (primarily via CYP3A4, forming inactive metabolites); <1% fecal.
Category D/X
Category C
Anticonvulsant
Anticonvulsant